Humacyte receives FDA full approval for SYMVESS in extremity arterial injury

Humacyte, Inc.

FDA grants full approval for SYMVESS as a vascular conduit for extremity arterial injury when autologous vein graft is not feasible.
In clinical trials, SYMVESS showed high patency rates and low rates of amputation and infection; results published in JAMA Surgery.
Sales team already recruited and trained; commercial launch preparation is underway.
SYMVESS is a first-in-class bioengineered human tissue, available off-the-shelf, eliminating the need for vein harvest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.